Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation

21.05.24 17:39 Uhr

Werte in diesem Artikel

249,80 CHF 1,90 CHF 0,77%


1.253,3 PKT 1,0 PKT 0,08%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

14.166,5 PKT -8,4 PKT -0,06%

1.949,8 PKT 0,6 PKT 0,03%

12.060,2 PKT 13,6 PKT 0,11%

1.650,3 PKT 1,3 PKT 0,08%

16.018,3 PKT 11,3 PKT 0,07%

3.594,4 PKT 20,4 PKT 0,57%

4.505,2 PKT -8,0 PKT -0,18%

15.884,0 PKT 10,9 PKT 0,07%

6.797,2 PKT 16,9 PKT 0,25%

Roche RHHBY obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States.The FDA granted this designation to inavolisib in combination with Ibrance (palbociclib) and Faslodex (fulvestrant) to treat adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.HR-positive breast cancer is the most prevalent type of breast cancer and roughly accounts for approximately 70% of cases.The designation is based on phase III INAVO120 study results, which showed that the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting. The study included 325 patients, who were randomly assigned to either the investigational or control treatment arm. Overall survival data were immature at this time, but a clear positive trend has been observed.Breakthrough Therapy Designation accelerates the development and regulatory review of drugs that are intended to treat fatal disease conditions where preliminary clinical evidence has indicated they may demonstrate substantial improvement over existing therapies.Data from the INAVO120 study is also being submitted to other global health authorities, including the European Medicines Agency.Apart from INAVO120, inavolisib is currently being evaluated in two additional company-sponsored late-stage clinical studies in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations.A phase III study, INAVO121, is evaluating inavolisib in combination with Faslodex versus Piqray (alpelisib) plus Faslodex in HR-positive/HER2-negative breast cancer post cyclin-dependent kinase 4/6 inhibitor and endocrine combination therapyAnother phase III study, INAVO122, is evaluating inavolisib combination with Perjeta (pertuzumab) plus Herceptin (trastuzumab) for subcutaneous injection (SC) versus Perjeta plus Herceptin for SC and optional physician's choice of endocrine therapy as a maintenance treatment in HER2-positive disease.Year to date, Roche’s shares have lost 10.5% against the industry’s 15.5% growth.Image Source: Zacks Investment ResearchRoche has a dominant position in the breast cancer market. The HER2 franchise includes Herceptin, Perjeta and Kadcyla. While Herceptin is being affected by biosimilar competition, the increased patient demand for Perjeta for adjuvant early breast cancer therapy maintains momentum. Kadcyla is also performing well, driven by increased demand from patients with residual disease after surgery. The approval of the fixed-dose combination of Perjeta and Herceptin as Phesgo strengthened the portfolio. Phesgo is gaining traction and maintaining momentum for this franchise.Approval of additional drugs for breast cancer will strengthen this franchise.However, competition in this lucrative space is stiff which will limit market share gains.Novartis NVS Kisqali has put up a spectacular performance in recent times. Sales of Kisqali grew strongly in the first quarter (+54%) across all regions, based on increasing recognition of consistently reported overall survival in HR+/HER2- advanced breast cancer. Kisqali is now one of the top growth drivers of NVS.The approval of Piqray for advanced or metastatic breast cancer further strengthened NVS’ breast cancer portfolio.Zacks Rank & Stocks to ConsiderRoche currently carries a Zacks Rank #4 (Sell).A couple of better-ranked stocks from the healthcare industry are Ligand Pharmaceuticals LGND and ANI Pharmaceuticals ANIP. Both stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.In the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 and 2025 earnings per share (EPS) has remained constant at $4.56 and $5.27, respectively. Shares of LGND are up 22.9% year to date.In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 EPS have improved from $4.43 to $4.44. Shares of ANIP have jumped 12.6% year to date. ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an earnings surprise of 53.90%, on average. Buy 5 Stocks BEFORE Election DayBiden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S. Don’t Wait. Download FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis ReportTo read this article on click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Roche

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Roche


Quelle: Zacks

Nachrichten zu Roche AG (Genussschein)

Analysen zu Roche AG (Genussschein)

17.06.2024Roche HoldDeutsche Bank AG
17.06.2024Roche SellGoldman Sachs Group Inc.
17.06.2024Roche Equal WeightBarclays Capital
17.06.2024Roche UnderweightJP Morgan Chase & Co.
03.06.2024Roche HoldDeutsche Bank AG
24.04.2024Roche KaufenDZ BANK
24.04.2024Roche OutperformBernstein Research
02.02.2024Roche KaufenDZ BANK
19.10.2023Roche KaufenDZ BANK
29.08.2023Roche BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
17.06.2024Roche HoldDeutsche Bank AG
17.06.2024Roche Equal WeightBarclays Capital
03.06.2024Roche HoldDeutsche Bank AG
31.05.2024Roche NeutralUBS AG
24.05.2024Roche HoldDeutsche Bank AG
17.06.2024Roche SellGoldman Sachs Group Inc.
17.06.2024Roche UnderweightJP Morgan Chase & Co.
03.06.2024Roche SellGoldman Sachs Group Inc.
30.05.2024Roche SellGoldman Sachs Group Inc.
16.05.2024Roche UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Roche AG (Genussschein) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"